COMMUNIQUÉS West-GlobeNewswire

NeoChord Announces Successful Completion of First Beating Heart Repair Procedures in China
03/09/2018
ST. LOUIS PARK, Minn., Sept. 03, 2018 (GLOBE NEWSWIRE) -- NeoChord, Inc. , a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve [...]
Transactions under Novozymes’ stock buyback program
03/09/2018
Please read the full announcement in the attached PDF Attachment 2018_52_Stock_Buybackprogram_EN
Total voting rights
03/09/2018
Summit Therapeutics plc (‘the Company’) Total voting rights Oxford, UK, and Cambridge, MA, US 3 September 2018 – Summit Therapeutics plc (AIM:SUMM, NASDAQ:SMMT), announces that in accordance with the FCA's Disclosure [...]
Progress Towards Clinical Development of IMP761 – a LAG-3 Agonist Antibody
03/09/2018
SYDNEY, Australia, Sept. 03, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep”, the “Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune [...]
Novo Nordisk A/S - Share repurchase programme
03/09/2018
Bagsværd, Denmark, 3 September 2018 - On 10 August 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]
GUERBET : Information sur les opération effectuées dans le cadre du programme de rachat d'actions
03/09/2018
Villepinte (France), le 03 septembre 2018 Le présent document a pour finalité de présenter les opérations réalisées dans le cadre du programme de rachat d'actions autorisé par l'Assemblée Générale Mixte du 25 mai 2018 [...]
Acarix Clinical Advisory Board meeting held in parallel to ESC-conference in Munich, Germany, confirms validity of its comprehensive clinical study program.
03/09/2018
Press release Malmö, Sept 3, 2018 Acarix Clinical Advisory Board meeting held in parallel to ESC-conference in Munich, Germany, confirms validity of its comprehensive clinical study program. Acarix AB (publ) ("Acarix [...]
Total voting rights
03/09/2018
Summit Therapeutics plc (‘the Company’) Total voting rights Oxford, UK, and Cambridge, MA, US 3 September 2018 – Summit Therapeutics plc (AIM:SUMM, NASDAQ:SMMT), announces that in accordance with the FCA's Disclosure [...]
Shire plc: Total voting rights
03/09/2018
Total Voting Rights September 3, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”), in accordance with 5.6.1R of the Financial Conduct Authority's (the “FCA”) Disclosure Guidance and Transparency Rules, notifies [...]
Trading in Novo Nordisk shares by board members, executives and associated persons on 31 August 2018
03/09/2018
Bagsværd, Denmark, 3 September 2018 - This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article [...]
Retail Partner ApS to distribute Acetium® lozenge in Danmark and Sweden
03/09/2018
Biohit Oyj Press release, September 3, 2018 at 10.00 p.m. local time (EET) Biohit Oyj and Retail partner ApS have signed an agreement for the distribution of the smoking cessation product Acetium lozenge in Danmark and [...]
Symphogen elects new Board members to support the Company's long-term development
03/09/2018
Press Release Copenhagen, 3 September 2018 Symphogen has held an extraordinary general meeting, where a number of changes to the Board of Directors were approved to support the Company's development and future financing [...]
Photocure ASA: Mandatory notification of trade
03/09/2018
Oslo, Norway, 3 September 2018: Photocure ASA (OSE: PHO), announces today that it has repurchased 1,121 own shares at NOK 0 per share in relation to the long-term incentive programme described in the stock exchange [...]
Nexstim Plc reports results of the supplementary Phase III E-FIT trial
03/09/2018
Company announcement, Helsinki, 3 September 2018 at 9:00AM Nexstim Plc reports results of the supplementary Phase III E-FIT trial Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or the " Company "), the targeted [...]
Shire plc: Rule 2.9 Announcement
03/09/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 3 September 2018 [...]
FIT Biotech Oy: Invitation to FIT Biotech Oy's briefing related to half-year financial report on September 6th 2018, at 10.00 AM.
03/09/2018
FIT Biotech Oy Press Release September 3 rd 2018, 08.45 EET Invitation to FIT Biotech Oy's briefing related to half-year financial report on September 6 th 2018, at 10.00 AM. FIT Biotech will publish its half-year [...]
Sensorion Announces Three Poster Presentations At The 55th Inner Ear Biology Workshop
03/09/2018
MONTPELLIER, France, Sept. 03, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN ), a biotech company specializing in the treatment of inner ear diseases, will present three posters at the 55 th Inner Ear Biology [...]
Tecan successfully completes the acquisition of NuGEN Technologies
03/09/2018
Männedorf, Switzerland, September 3, 2018 - The Tecan Group (SIX Swiss Exchange: TECN) announced today that it has successfully completed the acquisition of NuGEN Technologies, Inc. (NuGEN) on August 31, 2018. On August [...]
Sanofi: Cablivi(TM) (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
03/09/2018
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Cablivi(TM) (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP) First therapeutic approved for the treatment of [...]

Pages